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Edited by Ned ManteiAbstract Here, we examined phytoestrogens, isoﬂavones (gen-
istein, daidzein, glycitein, biochanin A and ipriﬂavone), ﬂavones
(chrysin, luteolin and apigenin), ﬂavonols (kaempferol and quer-
cetin), and a coumestan, a ﬂavanone and a chalcone (coumestrol,
naringenin and phloretin, respectively) by means of a DNA
microarray assay. A total of 172 estrogen responsive genes were
monitored with a customized DNA microarray and their expres-
sion proﬁles for the above phytoestrogens were compared with
that for 17b-estradiol (E2) using correlation coeﬃcients, or R
values, after a correlation analysis by linear regression. While
R values indicate the similarity of the response by the genes,
we also examined the genes by cluster analysis and by their
speciﬁcity to phytoestrogens (speciﬁc to genistein, daidzein or glyci-
tein) or gene functions. Several genes were selected from p53-
related genes (CDKN1A, TP53I11 and CDC14), Akt2-related
genes (PRKCD, BRCA1, TRIB3 and APPL), mitogen-activated
protein kinase-related genes (RSK and SH3BP5), Ras superfam-
ily genes (RAP1GA1, RHOC and ARHGDIA) and AP-1 family
and related genes (RIP140, FOS, ATF3, JUN and FRA2). We
further examined the extracts from two local crops of soy beans
(Kuro-daizu or Mochi-daizu) by comparing the gene expression
proﬁles with those of E2 or phytoestrogens as a ﬁrst step in uti-
lizing the expression proﬁles for various applications.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Phytoestrogen; Signal transduction1. Introduction
Phytoestrogens are chemicals that originate from plants with
estrogenic activity. They have attracted signiﬁcant attention
because of their ability to modulate the action of estrogen,
which may be used for anti-cancer agents, agents for hormone
therapy, dietary additives and supplements, and antimicrobialAbbreviations: E2, 17b-estradiol; GEN, genistein; DAI, daidzein; GLY,
glycitein; BIO, biochanin A; CHR, chrysin; LUT, luteolin; API, api-
genin; IPR, ipriﬂavone; KAE, kaempferol; QUE, quercetin; COU,
coumestrol; NAR, naringenin; PHL, phloretin; MAPK, mitogen-
activated protein kinase; SSC, 0.15 M NaCl and 0.015 M sodium
citrate
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doi:10.1016/j.febslet.2005.02.033agents [1–4]. The growing importance of phytoestrogens is
partly supported by genetic and genomic evidence of their ef-
fects. Understanding more about the gene function networks
and signal transduction pathways initiated or mediated by
these chemicals, therefore, will be of great beneﬁt to further
applications of phytoestrogens.
DNA mircroarrays have been used for the characteriza-
tion of phytoestrogens to examine genetic responses, to pre-
dict eﬀects and to discover new materials and sources [5–14].
One of the advantages of using DNA microarrays is that it
allows a comprehensive analysis of gene responses under
speciﬁc conditions, revealing gene networks and providing
signiﬁcant clues as to their mechanisms of function. Despite
concerns raised in some reports about the reliability of data
[15–17], increasing the statistical power through repetition of
the assay, selecting reliable genes, and reﬁning the statistical
approach by adopting a correlation analysis will all improve
the results. In this context, gene expression analysis using
customized DNA microarrays or focused microarrays is
attracting more attention because of these advantages along
with a reduction in the cost and time needed for the analysis
(reviewed in [18]). Statistical evaluation partly but signiﬁ-
cantly contributes to the use of focused microarrays. The
data obtained are incorporated into databases and will be
used for the classiﬁcation and screening of genes and for
giving annotations to genes for further application of the
data for mining useful information about target genes and
products, signaling pathways and their outcomes (reviewed
in [19–21]).
We previously developed a customized DNA microarray
containing estrogen responsive genes from human cells and
used it to analyze the eﬀects of natural estrogens, antagonists
of estrogens and industrial estrogenic chemicals [14,22]. Using
the DNA microarray, we characterized phytoestrogens to bet-
ter understand the eﬀects, mechanisms and outcomes of their
actions in human cells.2. Materials and methods
2.1. Chemicals
Natural estrogen, 17b-estradiol (E2), genistein (GEN) and chrysin
(CHR) were purchased from Sigma–Aldrich (St. Louis, MO, USA)
and daidzein (DAI) was obtained from Nacalai Tesque (Kyoto,
Japan). Glycitein, biochanin A (BIO), luteolin (LUT), apigeninblished by Elsevier B.V. All rights reserved.
R. Ise et al. / FEBS Letters 579 (2005) 1732–1740 1733(API), ipriﬂavone (IPR), coumestrol (COU), kaempferol (KAE), quer-
cetin (QUE), naringenin (NAR) and phloretin (PHL) were obtained
from Wako Pure Chemical Industries (Osaka, Japan). A 10 mM stock
of all compounds was dissolved in ethanol and the ﬁnal concentration
of solvent in the culture medium did not exceed 0.1%; this concentra-
tion did not aﬀect cell yields. Fetal bovine serum (FBS) was purchased
from HyClone (Logan, UT, USA). Penicillin–streptomycin solution
and trypsin/EDTA solution were all purchased from Life Technologies
(Grand Island, NY, USA). Soy beans (Kuro-daizu and Mochi-daizu;
gifts from Fujicco Co., Ltd. and Tottori Agricultural Experiment Sta-
tion, respectively) were homogenized in 15 mM Tris buﬀer (pH 8)
using a rolling mill at a ratio of 1 g of soy bean per 10 ml of buﬀer.
The resulting Tris homogenate was centrifuged twice at 15000 rpm
for 10 min, and the supernatant was collected and extracted with an
equal volume of acetone. The acetone extracts were dried under a
stream of nitrogen and the residue was dissolved in 1 ml of acetone,
and stored at 20 C prior to use. These soy bean extracts were used
at a concentration of 1 mg/ml in ethanol. All other chemicals and bio-
chemicals were of the highest quality available from commercial
sources.
2.2. Cell culture and RNA extraction
Human breast cancer MCF-7 cells were obtained from JCRB Cell
Bank (National Institute of Health Sciences, Tokyo, Japan) and rou-
tinely cultured in RPMI 1640 medium (Invitrogen, Carsbad, CA,
USA) supplemented with 10% FBS at 37 C in a humidiﬁed atmo-
sphere of 95% air and 5% CO2. Cells were cultured in phenol red-freeFig. 1. Chemical structures of phytoestrogens analyzed here. CheRPMI 1640 medium containing 10% dextran-coated charcoal-treated
FBS (DCC-FBS) for 6 days and treated with 10 nM of E2 or control
(0.1% ethanol) vehicle and 10 lM of phytoestrogens for 3 days. After
the cells were cultured for 3 days in the presence of chemicals at speciﬁc
concentrations, mRNA was puriﬁed using the PolyATract System
1000 (Promega, Madison, WI, USA) according to the manufacturers
instructions. The quality of mRNA was conﬁrmed by spectrophotom-
etry.
2.3. cDNA microarray analysis
A custom cDNA microarray (EstrArray) was manufactured by Inf-
oGenes (Tsukuba, Japan) by mechanical spotting of the cDNA (500
to 1.5 kb) of selected estrogen responsive genes as described previ-
ously [14]. For the EstrArray assay, biologically independent DNA
microarray assays were repeated ﬁve times for E2, genistein, daidzein
and glycitein, and twice for the other phytoestrogens. The analysis
using EstrArrays was performed as follows: each mRNA was labeled
with ﬂuorescent Cyanine 3 (Cy3)-dUTP for the treatment of chemicals
or Cyanine 5 (Cy5)-dUTP for the control vehicle at 42 C for 80 min
using Superscript II (Invitrogen) and random primers (a mixture of 6
mers and 9 mers). Both Cy3- and Cy5-labeled probes were mixed
and denatured under alkaline conditions for 1 h. After free ﬂuorescent
nucleotides were removed using CyScribe GFX Puriﬁcation kit (Amer-
sham Bioscience, Buckinghamshire, UK), probes were hybridized to
EstrArrays for 16 h in Hybridization buﬀer [5· 0.15 M NaCl and
0.015 M sodium citrate (SSC) containing 0.5% SDS] at 65 C. After
hybridization, slides were washed in 2· SSC/0.2% SDS for 5 min atmical formulas were modiﬁed to show the similarity to E2.
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rinsed in 0.05· SSC at room temperature for 5 min. Then, the buﬀer
remaining on the slide was removed by centrifugation. The ﬂuorescent
intensity was scanned with a ChipReader (Virtek, Ontario, Canada)
and quantitative values for the signals were calculated using IPLab
(Scanalytics, Fairfax, VA, USA) according to the manufacturers
instructions. Further data processing was carried out using Microsoft
Excel software. For each spot, the ratio of Cy3 and Cy5 signal inten-
sities (Cy3/Cy5) was calculated and log2-transformed. Each log2(Cy3/
Cy5) value was normalized by subtracting the average of log2(Cy3/
Cy5) values for 28 internal control genes (the genes that do not re-
spond to E2), and the duplicated log2(Cy3/Cy5) values for each gene
from two spots on a DNA microarray were averaged. In the case of
this analysis, the data for the spots with poor hybridization (the signal
areas of either Cy3 or Cy5 were below 50) were removed from the data
processing described above. This improved the correlation coeﬃcients
between duplicated sets of log2(Cy3/Cy5) values. Average-linkage hier-
archical clustering was applied using the Cluster program and the re-
sults were displayed with the TreeView program (both programs
were developed by Eisen et al. [23]). Correlation coeﬃcients between
E2 and phytoestrogens data sets were calculated in Excel and expressed
as R values.
The statistical analysis was done by a one-way analysis of variance
(ANOVA) test as follows: After normalization of DNA microarray
data, genes were removed if the absolute value of log2(Cy3/Cy5) for
the treatment with E2 was less than 1. The microarray data were calcu-
lated according to ANOVA test (P < 0.005) for E2, genistein, daidzein
and glycitein from ﬁve independent assays for each compound, and
signiﬁcant pairs of the compounds were selected by t-test (P
< 0.005). The values of fold changes were the averages of each
log2(Cy3/Cy5) value.
2.4. Real-time quantitative RT-PCR
mRNA was isolated using a PolyATract System 1000 (Promega) as
described previously [14]. The ﬁrst-strand cDNA was synthesized from
500 ng of mRNA using SuperScript II (Invitrogen). Quantitative PCR
was performed with a SYBR Premix Ex Taq (TakaraBio, Shiga,
Japan). After the denaturing of cDNA at 95 C for 10 s, the reaction
proﬁle was as follows: 40 cycles of denaturation at 95 C for 5 s, and
annealing and extension at 60 C for 20 s. After the PCR, a melting
curve was constructed by increasing the temperature from 65 to
95 C. b-Actin was used as an internal control. The ﬂuorescent signal
was plotted in real time against the temperature to produce melting
curves for each sample. Melting curves were then converted to melting
peaks by plotting the negative derivative of the ﬂuorescence with re-
spect to temperature against temperature. Thus, each speciﬁc PCR
product generates a speciﬁc signal and therefore a product-speciﬁc
melting peak. The ratios of each speciﬁc gene against b-actin were cal-
culated by standardizing the ratios of each control to the unit value.
The PCR was performed three times for each gene and the PCR prim-
ers were as follows: CDKN1A, 5 0-CCTTTCCCTTCAGTACCCTCT-
CA-3 0 and 5 0-ACTAGGGTGCCCTTCTTCTTGTG-3 0; RSK, 5 0-
CAAAGGACCTGGTGTCAAAGATG-30 and 5 0-AGATGTGGTG-
CATCCTGTCTGTT-3 0; RIP140, 5 0-TGCATTAGAACCATCTGG-
AGCA-3 0 and 5 0-CAGATGGAAGATTCCAGGTCCA-30; TP53I11,
5 0-CACGGACAAAGGGACACACA-3 0 and 5 0-GTACATGCCAA-
GGGGCAAGA-3 0; PRKCD, 5 0-GACCTCAAACTGGACAATG-
TGCT-30 and 5 0-ATCTCAGGGGCGATATAGTCAGG-3 0;
ARHGDIA, 5 0-CCTCACTAGCCTCTACTCCCTGT-3 0 and 5 0-ACT-
GAGGTGACTTGAGTGTTGG-3 0.Fig. 2. Cluster analysis of gene expression proﬁles after treatment with
estrogen or phytoestrogens. MCF-7 cells were treated with 10 nM
estrogen (17b-estradiol or E2) or 10 lM each of 13 phytoestrogens
(genistein, daidzein, glycitein, biochanin A, chrysin, luteolin, apigenin,
ipriﬂavone, kaempferol, quercetin, coumestrol, naringenin and phlore-
tin) for 72 h before mRNA extraction and DNA microarray analysis.
Gene expression proﬁles represent upregulated genes (red) and
downregulated genes (green) after treatment with E2 or phytoestro-
gens. The color scale shown indicates the ratios of the signal for each
chemical (Cy3 signal) to that for the vehicle (Cy5 signal).3. Results
3.1. Gene expression proﬁling for phytoestrogens by DNA
microarray assay
Using a customized DNA microarray, we examined expres-
sion proﬁles for phytoestrogens. A total of 13 phytoestrogens
(Fig. 1), ﬁve from isoﬂavones (genistein, daidzein, glycitein,
biochanin A and ipriﬂavone), three from ﬂavones (chrysin,
luteolin and apigenin), two from ﬂavonols (kaempferol and
quercetin), and one each from coumestans, ﬂavanones andchalcones (coumestrol, naringenin and phloretin, respectively),
were selected and analyzed for expression proﬁles of estrogen
responsive genes. A total of 172 genes were previously selected
from a total of approximately 20000 genes according to their
responses to E2 [14]. Among them, 108 genes showed upregu-
lation and 64 genes showed downregulation by E2 treatment.
When we used this DNA microarray system for phytoestro-
gens, similar although distinguishable expression proﬁles were
obtained (Fig. 2). The proﬁles for each phytoestrogen were
compared with that of E2 and their correlation coeﬃcients,
or R values, were calculated (Fig. 3). Isoﬂavones generally
showed high R values except for a synthetic phytoestrogen,
ipriﬂavone (R = 0.19) (Fig. 3, panels A–E). Genistein (at
10 lM) showed a very high R value (R = 0.93), which is close
to those of natural estrogens (0.929 for 10 nM estriol and 0.847
for 10 nM estrone) [14]. Note that the concentration of geni-
stein was 103-fold higher than those of these natural estrogens.
Biochanin A and daidzein showed slightly lower values, 0.79
and 0.74, respectively, suggesting the importance of the num-
ber of hydroxyl groups for the similarity. Glycitein showed
Fig. 3. Relationship of gene expression proﬁles between estrogen and phytoestrogens. Gene expression proﬁles after treatment with phytoestrogens
were compared with that of E2 in scatter-plot graphs. The phytoestrogens are: (A) genistein, (B) biochanin A, (C) daidzein, (D) glycitein, (E)
ipriﬂavone, (F) kaempferol, (G) quercetin, (H) apigenin, (I) chrysin, (J) luteolin, (K) phloretin, (L) coumestrol and (M) naringenin. The axes indicate
log2 values of the ratios of the signals after and before chemical treatment. The R values were calculated for each graph on the basis of linear
regression between the two proﬁles.
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the methoxyl group close to the 7-hydroxyl group of the ﬂa-
vone ring. The importance of this hydroxyl group was again
seen in ipriﬂavone, where the 7-hydroxyl group was replaced
with an isopropoxyl group. Flavanols, on the other hand,
showed intermediate values (0.68 for kaempferol and 0.53
for quercetin; Fig. 3, panels F and G, respectively). Flavones
examined here showed equivalent values ranging between
0.64 and 0.67, suggesting isoﬂavones to be more eﬀective in
terms of estrogen activity (Fig. 3, panels H–J). Phloretin,
coumestrol and naringenin showed even higher values (0.70–0.78; Fig. 3, panels K–M), although the structural basis for
such high values is not clear.
3.2. Genes responding to phytoestrogens
Among a total of 172 estrogen responsive genes, quite a por-
tion were categorized by their unique responses to either iso-
ﬂavones, ﬂavonols, ﬂavones or all phytoestrogens (their
outlines are included in Fig. 2 as a tree view). To understand
their speciﬁcity in a more reliable way, we repeated the assay
ﬁve times for E2, genistein, daidzein and glycitein, and exam-
ined the genes uniquely responding to one or a few
Table 1
List of genes showing unique responses among the treatment with E2,
genistein, daidzein and glycitein
Gene name Accession
No.
Fold change
E2 Genistein Daidzein Glycitein
Upregulation
PDZK1 NM_002614 2.84 2.48 2.12 0.49
ASNS NM_133436 2.64 1.74 0.41* 0.43*
PSAT1 NM_058179 2.58 1.45 0.67* 0.71*
WARS NM_004184 2.40 1.86 0.54* 0.41*
RBBP8 NM_002894 2.25 2.20 1.86 0.79*§
PCK2 NM_004563 2.21 1.25 0.54* 0.34*
ASS NM_054012 2.01 1.73 0.94*§ 0.27
STC2 NM_003714 2.00 0.78 0.29* 0.25
SLC7A5 NM_003486 1.91 1.51 1.17* 0.52*§
SLC1A4 NM_003038 1.66 1.22 0.58* 0.27*
IGFBP4 NM_001552 1.57 1.58 1.78 0.16*§
TPD52L1 NM_003287 1.29 1.41 2.02* 0.74
SHMT2 NM_005412 1.22 0.64 0.04* 0.05*
RPS6KA3 NM_004586 1.21 0.90 1.29 0.52
CDKN1A NM_000389 1.09 0.92 0.00 0.78*§
ULK1 NM_003565 1.05 0.41* 0.24* 0.10*
Downregulation
SLC12A2 NM_001046 3.21 2.78 2.22 1.45*§
ENO3 NM_001976 1.85 1.52 1.04 0.68*§
CBX1 NM_006807 1.09 0.86 0.08* 0.11
SCD NM_005063 1.03 0.11 0.64* 0.24
The results (the fold changes) of DNA microarray assays repeated ﬁve
times after the treatment of MCF-7 cells with E2, genistein, daidzein
and glycitein were ﬁrst analyzed by ANOVA test and the genes
showing statistically signiﬁcant responses between two compounds
were selected by t-test in the pairwise comparison for all four com-
pounds.
*P < 0.005 between the indicated compound and E2.
§P < 0.005 between the indicated compound and genistein.
P < 0.005 between the indicated compound and daidzein. The fold
changes are shown as log2 values.
Fig. 4. Cluster analysis of expression proﬁles for the genes related to
signal transduction in response to E2, genistein, daidzein, and
glycitein. The genes related to signal transduction were analyzed by
clustering the expression proﬁles after treatment with E2, genistein,
daidzein, and glycitein. DNA microarray analysis was performed
ﬁve times for each chemical and averages are shown here. The genes
were categorized into four groups: p53-related genes (CDKN1A,
TP53I11 and CDC14), Akt 2-related genes (PRKCD, BRCA1,
TRIB3 and APPL), MAPK-related genes (RSK and SH3BP5),
Ras superfamily genes (RAP1GA1, RHOC and ARHGDIA) and AP-
1 family and related genes (RIP140, FOS, ATF3, JUN and FRA2).
GenBank Accession Nos. were as follows: CDKN1A, NM_000389;
TP53I11, NM_006034; CDC14, NM_033331; PRKCD, NM_006254;
BRCA1, NM_007294; TRIB3, NM_021158; APPL, NM_012096;
RSK, NM_004586; SH3BP5, NM_004844; RAP1GA1, NM_002885;
RHOC, NM_175744; ARHGDIA, NM_004309.3; RIP140,
NM_003489; FOS, NM_005252; ATF3, NM_001674; JUN,
NM_002228; FRA2, NM_005253.
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upregulated or downregulated, respectively, in response to E2
showed statistically signiﬁcant diﬀerences (P < 0.005) for one
or a few compound(s) among the four. Among them, glycitein
showed the highest number of genes (15 out of 20), and two or
four genes showed signiﬁcant diﬀerences to two or three other
compounds, respectively. This indicates that this compound
showed relatively unique responses among them. Daidzein,
meanwhile, showed 13 genes and genistein showed only one
(ULK1). This is consistent with the results of correlation anal-
ysis between each compound and E2, where genistein, daidzein
and glycitein showed R values of 0.93, 0.74 and 0.59, respec-
tively (Fig. 3).3.3. Response of the genes related to signal transduction
The genes analyzed with our customized DNA microarray
include signal transduction-related genes. A total of 17 genes
listed in Fig. 4 are classiﬁed as p53-related genes (CDKN1A,
TP53I11 and CDC14), Akt2-related genes (PRKCD, BRCA1,
TRIB3 and APPL), mitogen-activated protein kinase
(MAPK)-related genes (RSK and SH3BP5), Ras superfamily
genes (RAP1GA1, RHOC and ARHGDIA) and AP-1 family
and related genes (RIP140, FOS, ATF3, JUN and FRA2).
Genistein and daidzein showed quite similar proﬁles to that
of E2, while glycitein showed a decreased response (SH3BP5and RIP140 for example) or the opposite response (CDKN1A
for example).
We further examined six genes related to signal pathways
which showed either upregulation (CDKN1A, RSK and
RIP140) or downregulation (TP53I11, PRKCD and ARHG-
DIA) on treatment with 10 nM E2, or 10 lM of either geni-
stein, daidzein or glycitein (Fig. 5). Since their responses
were generally poor, we also examined their responses by
real-time quantitative RT-PCR. All genes showed similar re-
sponses in both DNA microarray and RT-PCR analyses, con-
ﬁrming the results of the DNA microarray assay.3.4. Expression proﬁles for soy bean extracts
We next examined the extracts from two local crops of soy
beans (Kuro-daizu and Mochi-daizu). The results of DNA
microarray assays were compared with those with E2 and phy-
toestrogens (Table 2). Kuro-daizu and Mochi-daizu showed
similar proﬁles to each other, although Mochi-daizu generally
had higher R values. The proﬁle had a higher correlation to
that of daidzein (R = 0.73 or 0.75, respectively) than that of
E2 or genistein, and chrysin showed very high R values for
both extracts (R = 0.76 or 0.82, respectively).
Fig. 5. Real-time RT-PCR analysis of the genes showing up- or downregulation on treatment with E2, genistein, daidzein and glycitein. The
responses of signal-related genes were examined for the treatment with E2, genistein, daidzein or glycitein. The genes examined here are: (A and B)
CDKN1A, (C and D) RSK, (E and F) RIP140, (G and H) TP53I11, (I and J) PRKCD and (K and L) ARHGDIA. The results of DNA microarray
assays shown in Fig. 4 (panels A, C, E, G, I and K) and the results of real-time quantitative PCR (panels B, D, F, H, J and L) are shown. For real-
time quantitative PCR, experiments were repeated three times and their averages and the standard deviations are shown as bars and vertical lines in
the graphs, respectively. The ratios are shown as values of log2.
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4.1. Gene expression proﬁles for phytoestrogens
We here examined a total of 13 phytoestrogens from among
isoﬂavones, ﬂavones, ﬂavonols, coumestans, ﬂavanones and
chalcones using a customized DNA microarray. The DNA
microarray contains a total of 172 estrogen responsive genesselected from approximately 20000 human genes according
to the degree of the response and the type of gene function
[14,22]. We previously used this DNA microarray to proﬁle
the gene expression in response to natural estrogens and indus-
trial estrogenic chemicals [14]. The expression proﬁles obtained
for phytoestrogens (Fig. 1) were analyzed in two ways:
responses of genes by clustering the proﬁles (Fig. 2) and
Table 2
Relationship of gene expression proﬁles between either of the soy bean
extracts and estrogen or phytoestrogens
Chemical R value
Kuro-daizu Mochi-daizu
17b-Estradiol 0.55 0.63
Genistein 0.57 0.62
Biochanin A 0.58 0.66
Daidzein 0.73 0.75
Glycitein 0.41 0.55
Ipriﬂavone 0.25 0.25
Kaempferol 0.73 0.77
Quercetin 0.61 0.62
Apigenin 0.60 0.67
Chrysin 0.76 0.82
Luteolin 0.46 0.50
Phloretin 0.64 0.70
Coumestrol 0.55 0.62
Naringenin 0.68 0.70
Gene expression proﬁles of extracts from two local crops of soy beans
(Kuro-daizu or Mochi-daizu) were compared with those of E2 or
phytoestrogens. R values are the correlation coeﬃcients in the lin-
ear regression of the expression proﬁles between each compound and
the extracts.
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phytoestrogen (Fig. 3). Both analyses were further extended
by focusing on genes of speciﬁc proﬁles (Table 1) or functions
(Figs. 4 and 5) or by application of the statistical correlation
analysis for soy bean extracts (Table 2), respectively.
Estrogenic chemicals show sometimes quite unique re-
sponses depending on the time for treatments and the concen-
tration at which the cells are cultured. Hsieh et al. [24] showed
that genistein inhibits the growth of MCF-7 cells above 20 lM
but activates the growth at lower concentrations. We analyzed
here phytoestrogens at a concentration of 10 lM for treating
the cells cultured for 72 h. It will be of great interest to know
how the genes analyzed here respond to phytoestrogens under
diﬀerent conditions.
Several reports described speciﬁc and distinct gene expres-
sion proﬁles obtained in response to estrogenic chemicals.
Naciﬀ et al. [6] and Moggs et al. [17] described the diﬀerences
in gene expression induced with diﬀerent estrogenic chemicals
including genistein in the rodent female reproductive systems.
Such approaches are crucial in understanding the eﬀect of
estrogenic chemicals on diﬀerent tissues and eventually in pre-
dicting their physiologic eﬀects.
4.2. Responses of the genes related to signal transduction
The genes analyzed by speciﬁc functions in Fig. 4 can be cat-
egorized into p53-related genes (CDKN1A, TP53I11 and
CDC14), Akt2-related genes (PRKCD, BRCA1, TRIB3 and
APPL), MAPK-related genes (RSK and SH3BP5), Ras super-
family genes (RAP1GA1, RHOC and ARHGDIA) and AP-1
family and related genes (FRA2, ATF3, FOS, JUN and
RIP140) [18]. They were classiﬁed into the genes up-
(CDKN1A CDC14, TRIB3, APPL, RSK, SH3BP5, RAP1-
GA1, RIP140, FOS, ATF3 and FRA2) or downregulated
(TP53I11, PRKCD, BRCA1, RHOC and ARHGDIA) on
estrogen treatment. Among them, a total of six (three up-
and three downregulated) genes were analyzed by real-time
quantitative RT-PCR (Fig. 5). All genes examined here
showed similar responses to treatments with E2, genistein,
daizein and glycitein, and between DNA microarray andRT-PCR assays. Suppression of apoptosis seemed to be true
for these chemicals as observed by the p53-related genes:
upregulation of CDKN1A and downregulation of CDC14
and TP53I11. CDKN1A, or p21WAF-1, is an inhibitor of cy-
clin-dependent kinases preventing phosphorylation of retino-
blastoma family proteins and is highly expressed in MCF-7
cells [25]. While its transcription is upregulated by E2 treat-
ment as shown here (Figs. 4 and 5), genistein changes less
the expression of CDKN1A at either the transcription level
(Figs. 4 and 5) or the protein level [26]. For the negative regu-
lation of apoptosis-related genes by p53, increased expression
of CDKN1A is necessary and suﬃcient [27]. An increased
expression of CDKN1A could be mediated by the binding of
AP-1 family proteins to the promoter as observed in progester-
one regulation [28]. The involvement of PRKCD, or protein
kinase C d, in CDKN1A induction was suggested in phorbol
ester-induced growth arrest in MCF-7 cells [29]. Such a corre-
lation was observed here after the treatment with glycitein, as
the opposite response by CDKN1A to that observed after the
treatment with E2 (Table 1 and Fig. 5) seemed to be related
with less response by PRKCD (Fig. 5), and this may indicate
a less eﬀect of glycitein on the negative regulation of p53. As
for other p53-related genes analyzed here, CDC14 plays a role
in the cell cycle control possibly by dephosphorylating p53 [30]
and TP53I11 (PIG11) is a p53 target gene and may induce
apoptosis in response to chemicals [31].
Another pathway emerging here which possibly leads to
apoptosis involves Akt2, a protein serine/threonine protein ki-
nase, which mediates signals from epidermal growth factor
receptor to the apoptosis related genes, BRCA1 for example,
through activated Ras and phosphatidylinositol 3-kinase
(PI3K) in the estrogen and other signaling pathways [32].
The activity to inhibit apoptosis by Akt2 as well as Akt1 has
been a focus of attention for predicting the results of chemo-
therapy and radiotherapy [33] and estrogen signaling through
Ras-dependent non-genomic pathways involves Akt [34].
TRIB3 (TRB3) protein inhibits the kinase activity of Akt1,
and most likely Akt2 too, in insulin signaling by direct binding
[35] and may negatively regulate apoptosis as well. APPL, on
the other hand, mediates interaction between PI3K and Akt2
and modulates Akt2 functions upon mitogenic stimulation.
Although APPL (also known as DIP13a) mediates the apopto-
tic signal of DCC (deleted in colorectal cancer), a candidate tu-
mor-suppressor gene, the involvement of AKT2 in apoptotic
signaling is not clear [36]. As PRKCD and BRCA1 are, respec-
tively, related to MAPK pathways in estrogen signaling [37,38]
and activation of these proteins induces apoptosis [39,40],
downregulation of these genes with estrogen and phytoestro-
gens explains well the result of negative regulation of apoptosis
by estrogen stimulation.
Upregulation of the MAPK-related genes, SH3BP5 and
RSK, may result in either the enhancement of a MAPK family
protein, c-Jun N-terminal kinase (JNK) [41], which activates c-
jun (JUN), an AP-1 family protein [42], or the activation of
ERa directly through phosphorylation of the AF-1 domain
[43], respectively. Involvement of RSK in the non-genomic
estrogen signaling pathway to apoptosis was also reported
[34]. The genes belonging to the Ras superfamily analyzed here
are RAP1GA1 (Rap1GAP), RHOC (Rho C) and ARHGDIA
(Rho GDI), which are associated with factors transducing sig-
nals from receptors to a variety of signal mediators including
MAPK and Akt2. Upregulation of RAP1GA1, a GTPase-acti-
R. Ise et al. / FEBS Letters 579 (2005) 1732–1740 1739vating protein for Rap1, a Ras-like guanine-nucleotide-bind-
ing protein, may explain activation of the Ras/MAPK path-
way, whereas downregulation of both RHOC and
ARHGDIA (Rho GDI), a guanine nucleotide dissociation
inhibitor for Rho protein which regulates GDP/GTP ex-
changes and membrane association/dissociation of Rho [44],
may explain regulation of Rho function but the reason for this
and the outcome of this response is not clear.
A variety of AP-1 family (FRA2, ATF3 and FOS) and re-
lated (RIP140) genes showed upregulation after treatment with
E2 and other phytoestrogens. Among them, RIP140 is a widely
expressed corepressor and inhibits the transcriptional activity
of nuclear receptors including ERa [45]. AP-1 family proteins
and ERa sometimes form heterodimers and interact with
estrogen responsive elements located in the promoter or up-
stream/downstream of the promoter of a number of genes
and up- or downregulate their transcription (reviewed in
[46]). Compelling evidence was reported regarding a role for
AP-1 in apoptosis in various cell types where activation of
AP-1 family genes could result in activating or suppressing
apoptosis [47]. Elevated AP-1 binding activity and c-jun
(JUN) expression was reported in vitamin E succinate-induced
apoptosis in MCF-7 cells [48], though this may be further com-
pelling evidence of a role for AP-1 in MCF-7 cells. There was a
very small change in the transcription level of c-jun here (Fig.
4) probably partly due to this AP-1 behavior although the
signal could be transmitted through phosphorylation of the
N-terminal of JUN by JNK.4.3. DNA microarray analysis for natural products and their
applications
Based on the analysis of pure phytoestroges with the DNA
microarray, we attempted to examine soy bean extracts using
a similar approach (Table 2). The proﬁles of extracts from
two local crops (Kuro-daizu and Mochi-daizu) showed similar
R values to those of the phytoestrogens examined here but
gave quite diﬀerent values to each phytoestrogen. There were
higher correlations of the proﬁles of both extracts to daidzein
(R = 0.73 for Kuro-daizu or 0.75 for Mochi-daizu) and chrysin
(R = 0.76 or 0.82, respectively). Although soy bean extracts
contain genistein in an amount roughly equal to or sometimes
more than that of daidzein [49,50], the proﬁles both showed
higher R values for daidzein. This may be due to the modiﬁca-
tion of these phytoestrogens, which may change the proﬁles, or
diﬀerent estrogenic activity at diﬀerent concentrations.
Although the proﬁles were obtained with 10 lM of phytoestro-
gens, estimated concentrations of both genistein and daidzein
in the extracts are roughly 1/100 that (data not shown). Glyci-
tein, on the other hand, showed low R values (R = 0.41 or 0.55,
respectively), probably because the amounts are generally one
tenth those of genistein and daizein [49,50]. Higher R values
for kaempferol (R = 0.73 or 0.77, respectively) and chrysin
(R = 0.76 or 0.82, respectively) may be signiﬁcant although
the reason is not clear.
The approach described here would be useful for analyzing
plant extracts for various purposes including screening new
estrogenic materials, examining food processing methods, a
quality control of food products and understanding the eﬀects
of phytoestrogens. Estrogen activity or the activity of modulat-
ing estrogen eﬀects in plants and their extracts has been
reported. Although such attempts and analyses for under-standing the mechanism of action and outcomes have some-
times included the use of a DNA microarray assay (see
Section 1), the classiﬁcation based on expression proﬁles for
predicting outcomes was not satisfactory. Selecting appropri-
ate genes for DNA microarrays and statistical evaluation of
the selected genes related to signaling pathways as shown here
will provide more useful information for the application of
phytoestrogens.
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